JenaValve's target technology is about improving valve...

First 42 Last

Share
Profile

Follow
Biljor

303 Posts.

113

23/09/22

20:16

Post #: 63854728
Share

Originally posted by codeai: ↑

The history of Janavalve is rather interesting. It was one of the early TAVR manufacturers among the others who were acquired by Edwards and Medtronic around a decade ago.

Still as a standalone entity, It has received Breakthrough device approval by the FDA over a year ago and recently has raised US $100m with the support by the existing holders to proceed with the required clinical trial for pre marketing approval for its Trilogy valve.

Wondering what special about its valve and what valuation it has after the recent raise? As It is a private company, my best guess of its valuation must be well over a billion I reckoned.

https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/jenavalve-raises-100m-its-transfemoral-tavr-system
JenaValve raises $100M for its transfer oral TAVR system for severe aortic regurgitation
The company said it plans to use the funds to complete the research needed to gain approval from the U.S. Food and Drug Administration (FDA) for its Trilogy Heart Valve System for high-risk patients with symptomatic, severe aortic regurgitation (AR) and launch that system in the United States. The funds will also go toward improving the company’s data development and manufacturing efforts.
“JenaValve is committed to becoming the first and only FDA-approved transfemoral transcatheter valve system indicated for symptomatic, severe AR, addressing an estimated multi-billion-dollar U.S. market opportunity,” John Kilcoyne, JenaValve CEO, said in a statement. “This financing provides sufficient capital for us to conclude our ALIGN-AR clinical trial and prepare for a commercial launch in the U.S.”
The financing round was led by Bain Capital Life Sciences, but also included a mix of existing investors (Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Management, RMM and Venture Incubator) and first-time investors (Pictet Alternative Advisors SA, Qatar Investment Authority, Innovatus Capital Partners and Peijia Medical Limited).
“We continue to maintain conviction in the strength of JenaValve’s differentiated technology, its prospects for entering the U.S. market, and potential for substantial long-term value creation,” added Andrew Hack, MD, PhD, Bain Capital’s managing director and a member of the JenaValve Board of Directors.
The Trilogy Heart Valve System gained CE mark approval in May 2021. In June 2022, JenaValve provided an update on the first European patients to receive the solution, highlighting their “robust clinical outcomes.”
“The early results demonstrate that our Trilogy Heart Valve System can be safe and effective for patients suffering from AR and aortic stenosis outside a clinical trial,” Kilcoyne said at the time. “These results mark another milestone in JenaValve’s journey to becoming the standard of care for the treatment of AR, as these were the first implants of their kind in the real world.”

Expand

JenaValve's target technology is about improving valve styles currently available with the majority of the focus on regurgitation. This is a good move if you're only looking at the first generation valves and making them slightly safer (functionality is not better IMO).
In the current market, without us, JenaValve has a place to fill a specific need.
The JenaValve IMO is not even a blip on the radar to be our competition in the future. If it has any decent success, it'll be as a band aid waiting for our valves to hit the market.
Our valve solves the same problem and A LOT more. the technology is not even close.

all my opinion only based on my research on other valves. DYOR

AVR Price at posting: $24.00 Sentiment: Hold Disclosure: Held
16 Upvote

2 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 42 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.91		Change -0.210(3.43%)		Mkt cap ! $91.59M

Open	High	Low	Value	Volume
$6.01	$6.08	$5.85	$44.71K	7.43K

Buyers (Bids)

No.	Vol.	Price($)
1	857	$5.83

Sellers (Offers)

Price($)	Vol.	No.
$6.08	260	1

View Market Depth

No.	Vol.	Price($)
1	857	5.830
1	900	5.780
1	3000	5.620
1	1000	5.610
2	3500	5.600

Price($)	Vol.	No.
6.080	260	1
6.180	50	1
6.200	1000	1
6.400	130	1
6.500	255	1

Last trade - 15.51pm 26/06/2025 (20 minute delay)

AVR (ASX) Chart

JenaValve's target technology is about improving valve...

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

JenaValve&apos;s target technology is about improving valve...

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

JenaValve's target technology is about improving valve...